Clinical trials: Well Differentiated Liposarcoma, active
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated…
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT06422806
- Testing
- Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin
- Where
- 269 sites in United States, Canada and 1 more
- Volunteers
- 365 people
- Sponsor
- National Cancer Institute (NCI)
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital
Liposarcoma, Atypical Lipomatous Tumor
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
- Trial name
- ESPACE (NCT04224064)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Advanced Solid Tumors
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
- Trial name
- NCT05944224
- Testing
- SPH4336, Cadonilimab
- Where
- 16 sites in China
- Volunteers
- 63 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma.
- Conditions
- Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma
- Trial name
- NCT06843967
- Testing
- Mirdametinib, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Well-differentiated/Dedifferentiated Liposarcoma
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"
- Trial name
- NCT04438824
- Testing
- INCMGA00012, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center